Diarrhea News and Research RSS Feed - Diarrhea News and Research

Diarrhea is loose, watery stools. A person with diarrhea typically passes stool more than three times a day. People with diarrhea may pass more than a quart of stool a day. Acute diarrhea is a common problem that usually lasts 1 or 2 days and goes away on its own without special treatment. Prolonged diarrhea persisting for more than 2 days may be a sign of a more serious problem and poses the risk of dehydration. Chronic diarrhea may be a feature of a chronic disease.

Diarrhea can cause dehydration, which means the body lacks enough fluid to function properly. Dehydration is particularly dangerous in children and older people, and it must be treated promptly to avoid serious health problems.
Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen Research & Development, LLC today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc. [More]
CHLA pediatric specialist discusses how parents can help children prevent Ebola outbreak

CHLA pediatric specialist discusses how parents can help children prevent Ebola outbreak

For many months, the world has witnessed the Ebola virus spread and claim more than 4,400 lives in West African countries. On Oct. 8, the first confirmed adult Ebola patient identified in the United States died. The constant news coverage has heightened concern among parents who fear their children will become infected. Jill Hoffman, MD, a pediatric Infectious diseases specialist at Children's Hospital Los Angeles, discusses the facts about Ebola, how parents can help their children prevent further outbreak by teaching them good hygiene, and how CHLA is prepared to identify and treat suspected Ebola patients. [More]
Columbia University professor recommends vaccination for people travelling abroad

Columbia University professor recommends vaccination for people travelling abroad

Planning to travel outside the U.S. this holiday season? Check with your primary care provider or travel clinic when you book your flight. [More]
Second Dallas health worker has Ebola; CDC announces 'more robust' response

Second Dallas health worker has Ebola; CDC announces 'more robust' response

Seventy-six health-care workers who helped treat Ebola patient Thomas Eric Duncan are now being monitored for potential Ebola exposure. Forty-eight others are being watched because they had contact with Duncan. [More]
Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF). [More]
Web-based system could help improve detection of disease outbreaks, say researchers

Web-based system could help improve detection of disease outbreaks, say researchers

A web-based system that allows preschools and child care centers to report illnesses to local public health departments could improve the detection of disease outbreaks and allow resources to be mobilized more quickly, according to University of Michigan research to be presented Saturday, Oct. 11 at the American Academy of Pediatrics (AAP) National Conference & Exhibition in San Diego. [More]
Study shows potential of treating recurrent CDI with frozen fecal matter

Study shows potential of treating recurrent CDI with frozen fecal matter

A preliminary study has shown the potential of treating recurrent Clostridium difficile infection (a bacterium that is one of the most common causes of infection of the colon) with oral administration of frozen encapsulated fecal material from unrelated donors, which resulted in an overall rate of resolution of diarrhea of 90 percent, according to a study published in JAMA. [More]
Quick, forceful implementation of control interventions necessary to control Ebola outbreaks

Quick, forceful implementation of control interventions necessary to control Ebola outbreaks

New Ebola research demonstrates that quick and forceful implementation of control interventions are necessary to control outbreaks and avoid far worse scenarios. [More]
RBX2660 drug candidate highly effective against recurrent Clostridium difficile infection

RBX2660 drug candidate highly effective against recurrent Clostridium difficile infection

Rebiotix Inc. announced today that results of the Phase 2 PUNCH CD Study found that the overall efficacy of RBX2660 in the treatment of recurrent Clostridium difficile infection was 87.1%. The study also found that administration of RBX2660 was well-tolerated and demonstrated satisfactory safety in the 60-day interim analysis. [More]
CHOP joins CEGIR to advance treatment of eosinophilic disorders

CHOP joins CEGIR to advance treatment of eosinophilic disorders

The Children's Hospital of Philadelphia has joined a new consortium announced today by the National Institutes of Health to advance the treatment of chronic inflammatory diseases called eosinophilic disorders. [More]
Pediatric specialist in EGIDs helps lead $6.25 million NIH clinical research project

Pediatric specialist in EGIDs helps lead $6.25 million NIH clinical research project

A pediatric specialist in eosinophilic gastrointestinal diseases (EGIDs) at the University of Colorado School of Medicine and Children's Hospital Colorado will help lead a five-year, $6.25 million clinical research project recently funded by the National Institutes of Health. [More]
Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Astellas reported today that isavuconazole demonstrated successful outcomes in the treatment of mucormycosis according to data from the phase 3 isavuconazole VITAL study being presented at IDWeek on October 10, 2014, in Philadelphia, Pa. [More]
Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim today announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States. [More]
Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company, has announced the launch of its lead product Rasuvo (methotrexate) injection for patients with rheumatoid arthritis (RA), poly-articular-course juvenile idiopathic arthritis (pJIA) and psoriasis in the U.S. [More]
UPM researchers find way to enhance detection of rotavirus

UPM researchers find way to enhance detection of rotavirus

Researchers at the Universidad Politécnica de Madrid have found a way to enhance detection capacity of small concentrations of rotavirus. All this thanks to a new way to assess the biosensing response applied to an interferometric device. [More]
Family physician  answers questions related to Ebola virus

Family physician answers questions related to Ebola virus

According to the Centers for Disease Control, the outbreak of Ebola in four West African countries is one of the largest outbreaks of the disease in history. [More]
Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C). [More]
Rapid and coordinated response helps control Ebola outbreak in Nigeria

Rapid and coordinated response helps control Ebola outbreak in Nigeria

The Ebola outbreak in Nigeria appears to be nearing a possible end thanks to a rapid response coordinated by Nigeria's Emergency Operations Center with assistance from international partners, including the U.S. Centers for Disease Control and Prevention (CDC). [More]
Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel

Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel

Luminex Corporation today announced it has received U.S. FDA clearance to add three new targets to its xTAG Gastrointestinal Pathogen Panel (GPP). The targets include Adenovirus 40/41, Entamoeba histolytica and Vibrio cholerae. [More]
Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [More]